A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma

被引：0

作者：

Sonneveld, Pieter ^{[1
]}

Dimopoulos, Meletios A. ^{[2
]}

Boccadoro, Mario ^{[3
]}

Quach, Hang ^{[4
,5
]}

Ho, P. Joy ^{[6
,7
]}

Beksac, Meral ^{[8
]}

Hulin, Cyrille ^{[9
]}

Antonioli, Elisabetta ^{[10
,11
]}

Leleu, Xavier ^{[12
,13
]}

Mangiacavalli, Silvia ^{[14
]}

Perrot, Aurore ^{[15
]}

Cavo, Michele ^{[16
]}

Belotti, Angelo ^{[17
]}

Broijl, Annemiek ^{[1
]}

Gay, Francesca ^{[18
,19
]}

Mina, Roberto ^{[18
,19
]}

van de Donk, Niels W. C. J. ^{[20
]}

Katodritou, Eirini ^{[21
]}

Schjesvold, Fredrik ^{[22
,23
]}

Balari, Anna Sureda ^{[24
]}

Rosinol, Laura ^{[25
]}

Delforge, Michel ^{[26
]}

Roeloffzen, Wilfried ^{[27
]}

Silzle, Tobias ^{[28
]}

Vangsted, Annette ^{[29
]}

Einsele, Hermann ^{[30
]}

Spencer, Andrew ^{[31
]}

Hajek, Roman ^{[32
,33
]}

Jurczyszyn, Artur ^{[34
]}

Lonergan, Sarah ^{[1
]}

Ahmadi, Tahamtan ^{[35
]}

Liu, Yanfang ^{[36
]}

Wang, Jianping ^{[37
]}

Vieyra, Diego ^{[37
]}

van Brummelen, Emilie M. J. ^{[38
]}

Vanquickelberghe, Veronique ^{[39
]}

Sitthi-Amorn, Anna ^{[37
]}

de Boer, Carla J. ^{[38
]}

Carson, Robin ^{[37
]}

Rodriguez-Otero, Paula ^{[40
]}

Blade, Joan ^{[41
]}

Moreau, Philippe ^{[42
]}

机构：

[1] Erasmus MC, Dept Hematol, Canc Inst, 121552, Rotterdam, Netherlands

[2] Natl & Kapodistrian Univ Athens, Athens, Greece

[3] Univ Torino, Azienda Osped Univ Citta Salute & Sci Torino, Div Hematol, Myeloma Unit, Turin, Italy

[4] Univ Melbourne, Melbourne, Australia

[5] St Vincents Hosp, Melbourne, Australia

[6] Royal Prince Alfred Hosp RPAH, Inst Haematol, Camperdown, NSW, Australia

[7] Univ Sydney, Camperdown, NSW, Australia

[8] Ankara Univ, Ankara, Turkiye

[9] Hop Haut Leveque, Dept Hematol, Univ Hosp, Pessac, France

[10] Careggi Hosp, Dept Hematol, Florence, Italy

[11] Univ Florence, Florence, Italy

[12] Univ Poitiers, CHU, Poitiers, France

[13] Univ Poitiers, Inserm 1313, Poitiers, France

[14] IRCCS Fdn Policlin San Matteo, Div Hematol, Pavia, Italy

[15] Univ Toulouse, CHU Toulouse, IUCT O, UPS,Serv Hematol, Toulouse, France

[16] Univ Bologna, Ist Ematol Seragnoli, Dipartimento Med Specialist Diagnost & Sperimental, IRCCS Azienda Osped Univ Bologna, Bologna, Italy

[17] ASST Spedali Civili Brescia, Dept Hematol, Brescia, Italy

[18] Univ Torino, Div Hematol 1, AOU Citta Salute & Sci Torino, Turin, Italy

[19] Univ Torino, Dept Mol Biotechnol & Hlth Sci, Turin, Italy

[20] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Hematol, Amsterdam, Netherlands

[21] Theagenion Krankenhauses, Dept Hematol, Thessaloniki, Greece

[22] Oslo Univ Hosp, Oslo Myeloma Ctr, Dept Hematol, Oslo, Norway

[23] Univ Oslo, KG Jebsen Ctr B cell Malignancies, Oslo, Norway

[24] Univ Barcelona, Inst Catala Oncol Hosp, Hematol Dept, IDIBELL, Barcelona, Spain

[25] Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

[26] Univ Leuven, Leuven, Belgium

[27] Univ Med Ctr Groningen, Groningen, Netherlands

[28] Cantonal Hosp St Gallen, Dept Med Oncol & Hematol, St Gallen, Switzerland

[29] Rigshosp, Dept Hematol, Copenhagen, Denmark

[30] Univ Hosp Wurzburg, Dept Internal Med 2, Wurzburg, Germany

[31] Monash Univ, Alfred Hlth, Malignant Haematol & Stem Cell Transplantat Serv, Melbourne, Australia

[32] Univ Hosp Ostrava, Dept Hematooncol, Ostrava, Czech Republic

[33] Univ Ostrava, Fac Med, Ostrava, Czech Republic

[34] Jagiellonian Univ, Med Coll, Plasma Cell Dyscras Ctr, Dept Hematol, Krakow, Poland

[35] Genmab US Inc, Plainsboro, NJ USA

[36] Janssen Res & Dev LLC, Beijing, Peoples R China

[37] Janssen Res & Dev LLC, Spring House, PA USA

[38] Janssen Res & Dev LLC, Leiden, Netherlands

[39] Janssen Res & Dev, Beerse, Belgium

[40] Univ Navarra, Dept Hematol, Canc Ctr Clin, Pamplona, Navarra, Spain

[41] Univ Barcelona, Hosp Clin Barcelona, Inst Invest Biomed August Pi i Sunyer IDIBAPS, Barcelona, Spain

[42] Univ Hosp Hotel Dieu, Hematol Dept, Nantes, France

来源：

FUTURE ONCOLOGY | 2024年 / 20卷 / 38期

关键词：

blood; cancer; daratumumab; multiple myeloma; plain language summary; VRd;

D O I：

10.1080/14796694.2024.2394323

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

What is this summary about? This summary describes the first analysis of the PERSEUS study, which looked at adults with multiple myeloma that had never been treated before, also called newly diagnosed multiple myeloma. Multiple myeloma is a type of cancer in the blood, specifically in plasma cells within the soft, spongy tissue in the center of most bones, called the bone marrow. Researchers wanted to see if adding daratumumab (D) to a standard treatment of three other medicines called VRd, which stands for bortezomib (V), lenalidomide (R), and dexamethasone (d), could stop the multiple myeloma from getting worse and help participants live longer without multiple myeloma. Half of the participants were assigned to the treatment plan with daratumumab; they received D-VRd during initial treatment phases (induction and consolidation), followed by daratumumab as well as lenalidomide (D-R) in the maintenance phase. The other half of participants received treatment without daratumumab; they received VRd induction and consolidation followed by lenalidomide alone (R) maintenance. In addition, all participants were able to receive an autologous stem cell transplant, a procedure used to further help reduce multiple myeloma. What were the results? At the time of this analysis of PERSEUS, about 4 years after participants started the study, participants who received D-VRd treatment followed by D-R maintenance had a better response to treatment (as measured by specific markers of multiple myeloma) and were more likely to be alive and free from their multiple myeloma getting worse in comparison to participants who received VRd followed by R maintenance. Side effects (unwanted or undesirable effects of treatment) in both treatment groups were in line with the known side effects of daratumumab and VRd. What do the results mean? The results of the PERSEUS study showed that including daratumumab in D-VRd induction/consolidation and D-R maintenance was better for treating multiple myeloma than the current standard VRd treatment followed by R maintenance alone in adults with a new diagnosis of multiple myeloma who were also able to receive an autologous stem cell transplant. Of importance, there were no unexpected side effects in either group. Clinical Trial Registration: NCT02874742 (GRIFFIN) (ClinicalTrials.gov)

引用

页码：3043 / 3063

页数：21